Shares of biotech giant Moderna (NASDAQ: MRNA) closed trading on Friday, June 26, with a powerful 12% surge. This spike marked the culmination of an impressive six-month rally: from lows near $46 recorded in early June, the company's shares have risen by 125.51%. Behind this rapid ascent lies a series of fundamental factors, which I will analyze below.

The key catalyst was a positive decision by the FDA's Vaccines Advisory Committee. In a unanimous vote (9 out of 9), experts approved the safety and efficacy profile of mFLUSIVA (mRNA-1010)—the first-ever seasonal influenza vaccine based on mRNA technology, intended for individuals over 50 years of age. Such unanimity in the regulatory environment is rare, and it has virtually eliminated the main risk of uncertainty ahead of the final FDA verdict, expected on August 5.

Wall Street's View: Cautious Optimism Amid Records

Analysts' reactions were mixed. Piper Sandler raised its price target for MRNA to $77, while Jefferies increased it to $53, maintaining a "hold" rating. However, the median forecast for the stock still stands at $43.45, significantly below current quotes. Of the 16 analysts tracking the stock, most recommend holding positions rather than increasing them. Insider trading also shows a predominance of sales: 75 of the last transactions were sell-offs. This suggests that professional participants do not expect significant revenue growth from the flu vaccine until at least 2027.

Beyond the Flu: Restructuring and Oncology

In addition to its vaccination successes, Moderna has undergone a major business reorganization around three areas: vaccines, oncology, and rare diseases. This news alone boosted quotes by approximately 6.3%. Particular interest was sparked by Science Day on June 25, where the company presented an extensive development portfolio, including programs for in vivo CAR-T and T-cell engineering to treat oncological and autoimmune diseases. Furthermore, plans to invest in production capacities in Germany, including at sites that BioNTech intends to close, added another 8–12% to the stock's value over several sessions. The market interpreted this as a long-term bet on scaling ahead of new product launches in 2027–2028.

My Analysis: Moderna's rally is not just a speculative spike on vaccine news. It reflects a paradigm shift: the company is ceasing to be a "one-hit wonder" and is transforming into a platform player with a diversified portfolio. However, Wall Street's caution and insider sales signal that current levels already price in a significant portion of future successes. The key date for investors will be August 5—the FDA decision on mFLUSIVA. If it is positive, we will see a new wave of growth, but a correction here is likely inevitable.